BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

  June 4, 2025

   · 

  8 min read
• Press Releases

  Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

  June 4, 2025

   · 

  2 min read
• Press Releases

  New analyses reinforce long-term benefit of DARZALEX® (daratumumab) subcutaneous-based quadruplet regimen for patients with newly diagnosed multiple myeloma

  June 4, 2025

   · 

  18 min read
• Press Releases

  Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

  June 4, 2025

   · 

  35 min read
• Press Releases

  Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

  June 4, 2025

   · 

  14 min read
• Press Releases

  Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

  June 4, 2025

   · 

  29 min read
• Press Releases

  Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection

  June 4, 2025

   · 

  4 min read
• Press Releases

  DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

  June 4, 2025

   · 

  25 min read
• Press Releases

  Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

  June 4, 2025

   · 

  7 min read
• Press Releases

  Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

  June 4, 2025

   · 

  17 min read